- Home
- NSTS vs ANL Comparison
NSTS vs ANL Comparison
Compare NSTS & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NSTS
- ANL
- Stock Information
- Founded
- NSTS 1921
- ANL 2004
- Country
- NSTS United States
- ANL Cayman Islands
- Employees
- NSTS N/A
- ANL N/A
- Industry
- NSTS Savings Institutions
- ANL
- Sector
- NSTS Finance
- ANL
- Exchange
- NSTS Nasdaq
- ANL Nasdaq
- Market Cap
- NSTS 65.5M
- ANL 56.0M
- IPO Year
- NSTS N/A
- ANL 2023
- Fundamental
- Price
- NSTS $12.05
- ANL $1.44
- Analyst Decision
- NSTS
- ANL Hold
- Analyst Count
- NSTS 0
- ANL 1
- Target Price
- NSTS N/A
- ANL N/A
- AVG Volume (30 Days)
- NSTS 3.1K
- ANL 6.1K
- Earning Date
- NSTS 08-08-2025
- ANL 08-08-2025
- Dividend Yield
- NSTS N/A
- ANL N/A
- EPS Growth
- NSTS N/A
- ANL N/A
- EPS
- NSTS N/A
- ANL N/A
- Revenue
- NSTS $9,115,000.00
- ANL N/A
- Revenue This Year
- NSTS N/A
- ANL N/A
- Revenue Next Year
- NSTS N/A
- ANL N/A
- P/E Ratio
- NSTS N/A
- ANL N/A
- Revenue Growth
- NSTS 78.72
- ANL N/A
- 52 Week Low
- NSTS $9.37
- ANL $1.10
- 52 Week High
- NSTS $13.32
- ANL $3.89
- Technical
- Relative Strength Index (RSI)
- NSTS 46.01
- ANL 42.36
- Support Level
- NSTS $12.02
- ANL $1.48
- Resistance Level
- NSTS $12.39
- ANL $1.55
- Average True Range (ATR)
- NSTS 0.14
- ANL 0.05
- MACD
- NSTS -0.01
- ANL 0.00
- Stochastic Oscillator
- NSTS 51.92
- ANL 5.00
About NSTS NSTS Bancorp Inc.
NSTS Bancorp Inc is a savings and loan holding company regulated Federal Reserve Board. The company was formed to serve as the North Shore Trust and Savings stock holding company. The Bank is a wholly-owned subsidiary of the company and operates as a traditional savings institution focused on serving the banking needs of customers in market area of Lake County, Illinois and adjacent communities.
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.